Clinical trial
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
NCT01106014 is registered in ClinicalTrials.gov with Actelion as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
- Lead sponsor
- Actelion
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 1, 2009
- Completion date
- October 1, 2014
- Enrollment
- 1,156 (actual)
- Sites
- 182
Conditions
As the registry lists them; a condition with its own page is linked.